A Clinical Clinical Observation of CO2 Fractional Laser in Female Vaginal Repair

Sponsor
Xijing Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04492176
Collaborator
(none)
40
1
2
15
2.7

Study Details

Study Description

Brief Summary

  1. Vaginal atrophy is the most common indication in the treatment of vaginal rejuvenation. Its main manifestation is vaginal relaxation syndrome, which may be the early symptom of female pelvic floor dysfunction. It is a common gynecological physiological change in women. Its clinical manifestations include vaginal wall relaxation, decreased elasticity, poor dryness sensitivity, internal environment disorder, and so on. Vaginal exhaust, often combined with urinary incontinence, pelvic organ prolapse, chronic pelvic discomfort and other symptoms, seriously affecting patients'health and quality of sexual life. At present, there are many treatments for vaginal relaxation,vaginal constriction and laser therapy are the most effective and widely accepted treatments. Laser therapy with small trauma and short repair time has attracted much attention.

  2. CO2 fractional laser (Acupulse) stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection.

  3. It has been reported that CO2 lattice laser can stimulate collagen synthesis and rearrangement. It has also been reported that CO2 lattice laser may have important clinical significance in improving the morphology and function of vaginal epithelial cells.

Condition or Disease Intervention/Treatment Phase
  • Device: CO2 fractional laser(ACUPULSE,Lumenis)
N/A

Detailed Description

  1. Vaginal atrophy is the most common indication in the treatment of vaginal rejuvenation. Its main manifestation is vaginal relaxation syndrome, which may be the early symptom of female pelvic floor dysfunction. It is a common gynecological physiological change in women. Its clinical manifestations include vaginal wall relaxation, decreased elasticity, poor dryness sensitivity, internal environment disorder, and so on. Vaginal exhaust, often combined with urinary incontinence, pelvic organ prolapse, chronic pelvic discomfort and other symptoms, seriously affecting patients'health and quality of sexual life. At present, there are many treatments for vaginal relaxation,vaginal constriction and laser therapy are the most effective and widely accepted treatments. It should be noted that patients with vaginal constriction need anti-scar training for a long time after operation to prevent the effect of vaginal entrance narrowing and vaginal wall scar formation on the quality of life of patients during the repair period. Therefore, laser therapy with small trauma and short repair time has attracted much attention.

  2. CO2 fractional laser (Acupulse) stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal Internal environment and bacterial flora, and then reduce the probability of gynecological infection.

  3. It has been reported that CO2 lattice laser can stimulate collagen synthesis and rearrangement. It has also been reported that CO2 lattice laser may have important clinical significance in improving the morphology and function of vaginal epithelial cells. Our center has also passed the clinical observation ethical review of CO2 lattice laser to improve female vaginal relaxation in 2016, and completed the clinical trial at the end of 2017. The data further confirm that CO2 lattice laser can improve vaginal relaxation and is significantly effective for stress urinary incontinence.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Clinical Clinical Observation of CO2 Fractional Laser in Female Vaginal Repair: A Non-randomized, Open, Inter-group and Self-controlled Trial Before and After Treatment
Actual Study Start Date :
Aug 1, 2019
Actual Primary Completion Date :
Sep 30, 2020
Actual Study Completion Date :
Oct 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: CO2 fractional laser(ACUPULSE,Lumenis)

gradually withdrawn from inside to outside of vaginal. with CO2 fractional laser therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%,ACUPULSE,Lumenis) ,once a month for a total of 3 times .CO2 fractional laser stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection.

Device: CO2 fractional laser(ACUPULSE,Lumenis)
gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times

No Intervention: before treatment

the patient did not receive laser treatment

Outcome Measures

Primary Outcome Measures

  1. female sexual function FSFI score(Female Sexual Function Index ) [Changes from preoperative to 1 year after initial treatment]

    Questionnaire content involving sexual activity, intercourse, sexual stimulation, sexual desire or sexual interest, sexual excitement or sexual arousal, evaluation of female sexual function, questionnaire score ≤ 26.55 is considered female sexual dysfunction

  2. urinary incontinence questionnaire short form assessment [Changes from preoperative to 1 year after initial treatment]

    Evaluate urinary incontinence questionnaire short form assessment

  3. VHIS score in vaginal environment [Changes from preoperative to 1 year after initial treatment]

    Comprehensive evaluation of vaginal status by vulvar status, internal PH value, vaginal elasticity, guided endocrine secretion, and vaginal moistness

  4. vaginal pressure VTI data detection [Changes from preoperative to 1 year after initial treatment]

    Evaluate vaginal pressure by VTI data detection

  5. pelvic floor magnetic resonance MRI plain [Changes from preoperative to 1 year after initial treatment]

    Measure tissue structures in the pelvis

  6. scantransvaginal ultrasound [Changes from preoperative to 1 year after initial treatment]

    Measure the structures of the vagina

  7. histopathological biopsy [Changes before and 1month after treatment]

    5 cases were randomly selected for histopathological biopsy

Secondary Outcome Measures

  1. patient satisfaction assessment [Changes from preoperative to 1 year after initial treatment]

    Patient satisfaction: Very satisfied, satisfied, average, dissatisfied, very dissatisfied

  2. VAS Pain Assessment(Immediately after Treatment) [3 months]

    VAS pain scoring criteria (0-10 points): 0 points: no pain; less than 3 points: mild pain, can tolerate; 4 points 1-6 points: patients with pain and affect sleep, can still tolerate; 7 points-10 points : The patient has increasing pain, and the pain is intolerable

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Married women aged 25-75 with improvement needs;

  • Agree to participate in the experiment and sign the informed consent.

  • Female sexual dysfunction patients;

  • No other external treatment was performed before treatment at the lesion site.

  • VTI instrument was used for intravaginal pressure test to assess urinary incontinence and vaginal senility caused by chronic muscle dysfunction

Exclusion Criteria:
  • Pregnant or lactating women;

  • suffering from severe mental disorders, psychological disorders, personality disorders and major organ dysfunction;

  • Patients with severe hematological diseases, Sjogren's syndrome, systemic and therapeutic site infections;

  • Patients who took high doses of anticoagulants or hormones within one month;

  • Laser allergy history, photosensitive reactor;

  • Women with acute vaginitis or cervicitis;

  • Pap smear positive patients;

  • Female HIV (HIV), HPV (papillary virus), HSV (herpes simplex virus) positive patients;

  • Use of antifungal drugs, vaginal administration, vaginal irrigation and female sprays in the past 30 days

  • The condition of the visual field of laser surgery affected by ulceration and infection of the skin lesion

  • Those who have undergone vaginal tightening surgery with other substances or means

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dermatology Derpartment of Xijing Hospital Xi'an Shaanxi China 710032

Sponsors and Collaborators

  • Xijing Hospital

Investigators

  • Principal Investigator: Gang Wang, Dermatology Derpartment of Xijing Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gang Wang, MD, chief of dermatology, Xijing Hospital
ClinicalTrials.gov Identifier:
NCT04492176
Other Study ID Numbers:
  • XijingH-PF-20190718
First Posted:
Jul 30, 2020
Last Update Posted:
May 3, 2021
Last Verified:
Apr 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Gang Wang, MD, chief of dermatology, Xijing Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2021